CEFEPIME (CEFEPIME HYDROCHLORIDE) — all Canadian products
10 DINs
7 marketed/approved
0 in shortage
Every Health Canada Drug Identification Number whose active ingredient is CEFEPIME (CEFEPIME HYDROCHLORIDE), with holder, form, strength and current status, compared weekly against the Drug Product Database.
| DIN | Product | Company | Form | Route | Strength | Status | Shortage |
|---|---|---|---|---|---|---|---|
| 02467518 | APO-CEFEPIME | APOTEX INC | Powder For Solution | Intravenous | CEFEPIME (CEFEPIME HYDROCHLORIDE) 2 G | Marketed | |
| 02467496 | APO-CEFEPIME | APOTEX INC | Powder For Solution | Intramuscular; Intravenous | CEFEPIME (CEFEPIME HYDROCHLORIDE) 1 G | Marketed | |
| 02319020 | CEFEPIME FOR INJECTION | APOTEX INC | Powder For Solution | Intramuscular; Intravenous | CEFEPIME (CEFEPIME HYDROCHLORIDE) 1 G | Approved | |
| 02499088 | CEFEPIME FOR INJECTION USP | HIKMA CANADA LIMITED | Powder For Solution | Intramuscular; Intravenous | CEFEPIME (CEFEPIME HYDROCHLORIDE) 1 G | Approved | |
| 02499096 | CEFEPIME FOR INJECTION USP | HIKMA CANADA LIMITED | Powder For Solution | Intravenous | CEFEPIME (CEFEPIME HYDROCHLORIDE) 2 G | Marketed | |
| 02464004 | CEFEPIME FOR INJECTION, USP | QILU PHARMACEUTICAL CO., LTD. | Powder For Solution | Intravenous | CEFEPIME (CEFEPIME HYDROCHLORIDE) 2 G | Approved | |
| 02463997 | CEFEPIME FOR INJECTION, USP | QILU PHARMACEUTICAL CO., LTD. | Powder For Solution | Intravenous; Intramuscular | CEFEPIME (CEFEPIME HYDROCHLORIDE) 1 G | Approved | |
| 02319039 | CEFEPIME FOR INJECTION | APOTEX INC | Powder For Solution | Intravenous | CEFEPIME (CEFEPIME HYDROCHLORIDE) 2 G | Dormant | |
| 02163632 | MAXIPIME FOR INJECTION -PWS IV IM 1G | BRISTOL-MYERS SQUIBB CANADA | Powder For Solution | Intravenous; Intramuscular | CEFEPIME (CEFEPIME HYDROCHLORIDE) 1 G | Cancelled Post Market | |
| 02163640 | MAXIPIME FOR INJECTION-PWS IV 2GM | BRISTOL-MYERS SQUIBB CANADA | Powder For Solution | Intravenous | CEFEPIME (CEFEPIME HYDROCHLORIDE) 2 G | Cancelled Post Market |
Browse other molecules: